HIGH

Fresenius Kabi Famotidine Injection Recall Expands for Microbial Contamination in 2.2 Million Vials

Fresenius Kabi USA, LLC recalls 2,199,850 vials of Famotidine Injection, U.S. distribution nationwide plus Alaska, Hawaii and Puerto Rico after endotoxin testing concerns. The microbial contamination risk prompted an immediate stop-use order. Healthcare providers and patients should follow recall guidance and seek alternatives through their providers.

Quick Facts at a Glance

Recall Date
November 6, 2025
Hazard Level
HIGH
Brands
Famotidine, Fresenius Kabi USA, LLC
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT

Hazard Information

Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Fresenius Kabi USA, LLC or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Famotidine Injection is a hospital medication used to reduce stomach acid production. It is administered by healthcare professionals in clinical settings.

Why This Is Dangerous

Contaminated sterile injections pose risk of severe infection or endotoxin-related reactions if administered.

Industry Context

This recall is not part of a broader industry pattern, based on the current notice.

Real-World Impact

Hospitals and clinics must identify affected lots and replace or discard these vials. Consumers may face delays in treatment if alternatives are not readily available.

Practical Guidance

How to identify if yours is affected

  1. Check the lot numbers on the vial packaging: 6133156, 6133194, 6133388
  2. Verify expiry dates: 08/2026 and 10/2026
  3. Confirm NDC 63323-739-11 (unit of use) or 63323-739-12 (unit of sale)

Where to find product info

Identification is on the vial label and the accompanying packaging. FDA recall notices also list the lot numbers.

What timeline to expect

Refunds or replacements are coordinated through Fresenius Kabi and healthcare facilities; timelines vary by institution.

If the manufacturer is unresponsive

  • Contact Fresenius Kabi customer service for escalation
  • File a report with your hospital or supplier if replacements are delayed

How to prevent similar issues

  • Implement lot-level inventory controls to segregate recalled vials
  • Establish supplier notification processes for endotoxin-related issues
  • Verify endotoxin testing results prior to patient administration when possible

Documentation advice

Keep recall letters, batch numbers, and any correspondence with suppliers or healthcare providers.

Product Details

Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL vials. NDC 63323-739-11 (unit of use) and 63323-739-12 (unit of sale). Quantity: 2,199,850 vials. Sold nationwide in the United States, including AK, HI, and PR. Lot numbers include 6133156, 6133194, 6133388. Expiry dates listed as 08/2026 and 10/2026.

Reported Incidents

No specific injuries or illnesses are described in the recall notice. The action is precautionary and based on quality testing results.

Key Facts

  • 2,199,850 vials recalled
  • Lot numbers: 6133156, 6133194, 6133388
  • Expiry dates: 08/2026, 10/2026
  • Nationwide distribution including AK, HI, PR

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANT
Injury Types
POISONING

Product Details

Model Numbers
Lot #: 6133156
6133194
6133388
UPC Codes
63323-739
63323-739-11
63323-739-12
Affected States
ALL
Report Date
December 3, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more